Login to Your Account



Tesaro shares climb as nausea drug hits phase III endpoints

By Michael Fitzhugh
Staff Writer

Tuesday, May 13, 2014
Investors drove Tesaro Inc. shares up 21 percent Monday (NASDAQ:TSRO) on news that the company hit both its primary and secondary endpoints in a phase III trial of rolapitant, its top hope for breaking into the $1.5 billion U.S. market for drugs preventing chemotherapy-induced nausea and vomiting (CINV).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription